SAR and chemistry of Aurora kinase inhibitors: Discovery of PF-3814735, an oral clinical candidate
Samit K. Bhattacharya(Pfizer (United States)), Xumiao Zhao(Pfizer (United States)), Chunyan Su(Peking University), Matthew A. Marx(Mirati Therapeutics (United States)), K. LeRoi Nelson(Pfizer (United States)), David M. Briere(Mirati Therapeutics (United States)), Mary E. Campbell(Mitchell Institute), Joel T. Arcari(Pfizer (United States)), Tracy Boyden(Pfizer (United States)), Vincent Bernardo(Pfizer (United States)), Courtney Williams(Pfizer (United States)), Jun Xiao(Hunan Normal University), Michael J. Luzzio(Pfizer (United States)), Kristina Rafidi(Pfizer (United States)), Jitesh P. Jani, Leslie R. Pustilnik(Pfizer (United States)), John Jakubczak(University of Rochester), Gonghua Pan(Pfizer (United States)), Stefanus J. Steyn(Pfizer (United States)), Donn G. Wishka(Pfizer (United States)), Kostantinos Tsaparikos(Pfizer (United States)), Bruce D. Cohen(Pfizer (United States)), Erling O. Emerson(Pfizer (United States)), Chao Li(Eli Lilly (United States)), Shusen Sun(Pfizer (United States)), Ann Marie Rossi(Pfizer (United States)), Kevin Coleman(Arvinas (United States)), Kwansik Yoon(Pfizer (United States)), James D. Moyer(Pfizer (United States)), Rick Shepard(Pfizer (United States))
Cancer Research
May 1, 2008
Cited by 5
Related Papers
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
|Proceedings of the National Academy of Sciences|2016|825
Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ
|Journal of Clinical Investigation|2003|712
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460